Brokerages Set Cryoport, Inc. (NASDAQ:CYRX) PT at $11.83

Shares of Cryoport, Inc. (NASDAQ:CYRX) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $11.83.

Several analysts have recently issued reports on the company. Guggenheim initiated coverage on Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Cryoport in a report on Thursday. Roth Mkm reissued a “buy” rating and issued a $15.00 price objective on shares of Cryoport in a research report on Tuesday, April 1st. Finally, UBS Group raised their target price on shares of Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st.

Cryoport Stock Performance

Shares of CYRX opened at $5.77 on Monday. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $6.12 and a 200-day simple moving average of $7.10. Cryoport has a 52-week low of $4.58 and a 52-week high of $17.95. The company has a market capitalization of $287.98 million, a PE ratio of -1.71 and a beta of 1.81.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The business had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter last year, the business posted ($0.29) earnings per share. Equities research analysts predict that Cryoport will post -0.99 earnings per share for the current fiscal year.

Insider Activity at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. The trade was a 0.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have sold 19,830 shares of company stock worth $118,353. 10.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Cryoport

Several large investors have recently made changes to their positions in CYRX. Bullseye Asset Management LLC raised its position in Cryoport by 58.7% in the third quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock valued at $1,737,000 after purchasing an additional 79,244 shares during the period. Barclays PLC lifted its position in Cryoport by 272.9% during the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock worth $660,000 after acquiring an additional 59,582 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Cryoport in the third quarter valued at approximately $3,405,000. SG Americas Securities LLC raised its stake in shares of Cryoport by 44.8% during the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock valued at $1,142,000 after purchasing an additional 45,430 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after purchasing an additional 1,764 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.